Treatments of Herpes zoster ophthalmicus: an overview of current therapeutic and prophylactic strategies Review article
Article Sidebar
Published:
Aug 14, 2024
Keywords:
shingles, herpes zoster ophthalmicus, ocular shingles, therapeutic options, preventing options, chickenpox
Main Article Content
Abstract
Shingles and its complications are a significant issue in medicine, primarily affecting the elderly. The condition is caused by the reactivation of infection by a virus, whose primary clinical manifestation is chickenpox. A particular form of shingles is the ocular type, where changes occur along the branches of the trigeminal nerve. During the course of the disease, numerous symptoms concerning the eyeball may occur, and the patient is exposed to many dangerous and troublesome complications. In the following article, we will present available therapeutic and preventive options aimed at treating and preventing Herpes zoster ophthalmicus.
Downloads
Download data is not yet available.
Article Details
How to Cite
1.
Chamera-Cyrek K, Dyląg L, Sikora O, Żaczek B, Cwalina O, Molga M, Mrugała Z, Baran JM, Rowiński D, Podczerwińska A, Kuzminski C, Pawlicka I, Roszkowska AM, Kozak M. Treatments of Herpes zoster ophthalmicus: an overview of current therapeutic and prophylactic strategies. Ophthatherapy [Internet]. 2024Aug.14 [cited 2024Dec.3];00. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/3136
Issue
Section
Articles
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Kuchar E. Półpasiec – objawy, przyczyny, powikłania, leczenie .
2. Tsatsos M, Athanasiadis I, Myrou A et al. Herpes Zoster Ophthalmicus: A Devastating Disease Coming Back with Vengeance or Finding Its Nemesis? J Ophthalmic Vis Res. 2022; 17(1): 123-29. http://doi.org/10.18502/jovr.v17i1.10177.
3. Cohen JI. Clinical practice: Herpes zoster. N Engl J Med. 2013; 369(3): 255-63. http://doi.org/10.1056/NEJMcp1302674.
4. Kahloun R, Attia S, Jelliti B et al. Ocular involvement and visual outcome of herpes zoster ophthalmicus: review of 45 patients from Tunisia, North Africa. J Ophthalmic Inflamm Infect. 2014; 4: 25. http://doi.org/10.1186/s12348-014-0025-9.
5. Bhavsar A, Lonnet G, Wang C et al. Increased Risk of Herpes Zoster in Adults ≥50 Years Old Diagnosed With COVID-19 in the United States. Open Forum Infect Dis. 2022; 9(5): ofac 118. http://doi.org/10.1093/ofid/ofac118.
6. Kański JJ, Kubicka-Trząska A. Choroby infekcyjne oczu. Górnicki Wydawnictwo Medyczne, Wrocław 2018.
7. Marra F, Ruckenstein J, Richardson K. A meta-analysis of stroke risk following herpes zoster infection. BMC Infect Dis. 2017; 17(1): 198. http://doi.org/10.1186/s12879-017-2278-z.
8. Prost M. Zapalenie spojówek w przebiegu półpaśca lub ospy wietrznej .
9. Kański JJ, Kubicka-Trząska A. Wirus ospy wietrznej i półpaśca .
10. Kański JJ, Bowling B. Okulistyka kliniczna. Elsevier Urban & Partner, Wrocław 2013: 189-93.
11. Niżankowska M. Okulistyka – podstawy kliniczne. Wydawnictwo Lekarskie PZWL, Warszawa 2007: 186-7.
12. Bergstrom R, Tripathy K. Acute Retinal Necrosis. 2023 Aug 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan.
13. >Krzywy-Daroszewska E. Ostra martwica siatkówki 14. Rosenberg L. Herpes Zoster Glaucoma. An overview of its mechanisms and treatment .
15. Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BMJ. 2003; 326(7392): 748-50. http://doi.org/10.1136/bmj.326.7392.748.
16. Mordarski S. Patomechanizm i leczenie bólu neuropatycznego, ze szczególnym uwzględnieniem neuralgii popółpaścowej. Ból. 2004; 5: 49-53.
17. Michalska-Bańkowska A, Lis-Święty A, Bańkowski M et al. Prophylaxis and treatment of acute and chronic postherpetic neuralgia. Dermatology Review/Przegląd Dermatologiczny. 2014; 101(3): 205-10. http://doi.org/10.5114/dr.2014.43812.
18. Delengocky T, Bui CM. Complete ophthalmoplegia with pupillary involvement as an initial clinical presentation of herpes zoster ophthalmicus. J Am Osteopath Assoc. 2008; 108(10): 615-21.
19. Gajewski P, Duszczyk E, Zaborowski P. Interna Szczeklika. Podręcznik chorób wewnętrznych. 2012: 2215-9.
20. Colin J, Prisant O, Cochener B et al. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology. 2000; 107(8): 1507-11. http://doi.org/10.1016/s0161-6420(00)00222-0.
21. Wood MJ, Shukla S, Fiddian AP et al. Treatment of acute herpes zoster: effect of early (< 48 h) versus late (48-72 h) therapy with acyclovir and valacyclovir on prolonged pain. J Infect Dis. 1998; 178(Suppl. 1): S81-4. http://doi.org/10.1086/514271.
22. Panickar A, Serpell M. Guidelines for General Practitioners on Treatment of Pain in Post-Herpetic Neuralgia .
23. Werner RN, Ghoreschi K. Herpes zoster – Prävention, Diagnostik und Behandlung [Herpes zoster-prevention, diagnosis, and treatment]. Hautarzt. 2022; 73(6): 442-51. German. http://doi.org/10.1007/s00105-022-04992-9.
24. Binder A, Bruxelle J, Rogers P et al. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig. 2009; 29(6): 393-408. http://doi.org/10.2165/00044011-200929060-00003.
25. Dworkin RH, Johnson RW, Breuer J et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007; 44(Suppl. 1): S1-26. http://doi.org/10.1086/510206.
26. Saczka K. Program Szczepień Ochronnych na rok 2024.
27. Charakterystyka Produktu Leczniczego. VARIVAX .
28. Charakterystyka Produktu Leczniczego. VARILRIX .
29. Portal Medycyna Praktyczna. Baza leków. Shingrix .
30. Strezova A, Diez-Domingo J, Al Shawafi K et al. Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination. Open Forum Infect Dis. 2022; 9(10): ofac485. http://doi.org/10.1093/ofid/ofac485.
2. Tsatsos M, Athanasiadis I, Myrou A et al. Herpes Zoster Ophthalmicus: A Devastating Disease Coming Back with Vengeance or Finding Its Nemesis? J Ophthalmic Vis Res. 2022; 17(1): 123-29. http://doi.org/10.18502/jovr.v17i1.10177.
3. Cohen JI. Clinical practice: Herpes zoster. N Engl J Med. 2013; 369(3): 255-63. http://doi.org/10.1056/NEJMcp1302674.
4. Kahloun R, Attia S, Jelliti B et al. Ocular involvement and visual outcome of herpes zoster ophthalmicus: review of 45 patients from Tunisia, North Africa. J Ophthalmic Inflamm Infect. 2014; 4: 25. http://doi.org/10.1186/s12348-014-0025-9.
5. Bhavsar A, Lonnet G, Wang C et al. Increased Risk of Herpes Zoster in Adults ≥50 Years Old Diagnosed With COVID-19 in the United States. Open Forum Infect Dis. 2022; 9(5): ofac 118. http://doi.org/10.1093/ofid/ofac118.
6. Kański JJ, Kubicka-Trząska A. Choroby infekcyjne oczu. Górnicki Wydawnictwo Medyczne, Wrocław 2018.
7. Marra F, Ruckenstein J, Richardson K. A meta-analysis of stroke risk following herpes zoster infection. BMC Infect Dis. 2017; 17(1): 198. http://doi.org/10.1186/s12879-017-2278-z.
8. Prost M. Zapalenie spojówek w przebiegu półpaśca lub ospy wietrznej .
9. Kański JJ, Kubicka-Trząska A. Wirus ospy wietrznej i półpaśca .
10. Kański JJ, Bowling B. Okulistyka kliniczna. Elsevier Urban & Partner, Wrocław 2013: 189-93.
11. Niżankowska M. Okulistyka – podstawy kliniczne. Wydawnictwo Lekarskie PZWL, Warszawa 2007: 186-7.
12. Bergstrom R, Tripathy K. Acute Retinal Necrosis. 2023 Aug 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan.
13. >Krzywy-Daroszewska E. Ostra martwica siatkówki 14. Rosenberg L. Herpes Zoster Glaucoma. An overview of its mechanisms and treatment .
15. Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BMJ. 2003; 326(7392): 748-50. http://doi.org/10.1136/bmj.326.7392.748.
16. Mordarski S. Patomechanizm i leczenie bólu neuropatycznego, ze szczególnym uwzględnieniem neuralgii popółpaścowej. Ból. 2004; 5: 49-53.
17. Michalska-Bańkowska A, Lis-Święty A, Bańkowski M et al. Prophylaxis and treatment of acute and chronic postherpetic neuralgia. Dermatology Review/Przegląd Dermatologiczny. 2014; 101(3): 205-10. http://doi.org/10.5114/dr.2014.43812.
18. Delengocky T, Bui CM. Complete ophthalmoplegia with pupillary involvement as an initial clinical presentation of herpes zoster ophthalmicus. J Am Osteopath Assoc. 2008; 108(10): 615-21.
19. Gajewski P, Duszczyk E, Zaborowski P. Interna Szczeklika. Podręcznik chorób wewnętrznych. 2012: 2215-9.
20. Colin J, Prisant O, Cochener B et al. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology. 2000; 107(8): 1507-11. http://doi.org/10.1016/s0161-6420(00)00222-0.
21. Wood MJ, Shukla S, Fiddian AP et al. Treatment of acute herpes zoster: effect of early (< 48 h) versus late (48-72 h) therapy with acyclovir and valacyclovir on prolonged pain. J Infect Dis. 1998; 178(Suppl. 1): S81-4. http://doi.org/10.1086/514271.
22. Panickar A, Serpell M. Guidelines for General Practitioners on Treatment of Pain in Post-Herpetic Neuralgia .
23. Werner RN, Ghoreschi K. Herpes zoster – Prävention, Diagnostik und Behandlung [Herpes zoster-prevention, diagnosis, and treatment]. Hautarzt. 2022; 73(6): 442-51. German. http://doi.org/10.1007/s00105-022-04992-9.
24. Binder A, Bruxelle J, Rogers P et al. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig. 2009; 29(6): 393-408. http://doi.org/10.2165/00044011-200929060-00003.
25. Dworkin RH, Johnson RW, Breuer J et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007; 44(Suppl. 1): S1-26. http://doi.org/10.1086/510206.
26. Saczka K. Program Szczepień Ochronnych na rok 2024.
27. Charakterystyka Produktu Leczniczego. VARIVAX .
28. Charakterystyka Produktu Leczniczego. VARILRIX .
29. Portal Medycyna Praktyczna. Baza leków. Shingrix .
30. Strezova A, Diez-Domingo J, Al Shawafi K et al. Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination. Open Forum Infect Dis. 2022; 9(10): ofac485. http://doi.org/10.1093/ofid/ofac485.